ChiCTR2600126684 版本V1.0 版本创建时间2026/06/13 18:21:23 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126684 

最近更新日期:

Date of Last Refreshed on:

2026-06-13 18:21:15 

注册时间:

Date of Registration:

2026-06-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超声引导下介入诊疗联合多模态超声在乳腺病变中的应用研究

Public title:

Application of Ultrasound-Guided Interventional Therapy Combined with Multimodal Ultrasonography in Breast Lesions

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下介入诊疗联合多模态超声在乳腺病变中的应用研究

Scientific title:

Application of Ultrasound-Guided Interventional Therapy Combined with Multimodal Ultrasonography in Breast Lesions

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐瑞芳 

研究负责人:

徐瑞芳 

Applicant:

Ruifang Xu 

Study leader:

Ruifang Xu 

申请注册联系人电话:

Applicant telephone:

+86 10 63139826

研究负责人电话:

Study leader's
telephone:

+86 10 63139826

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

drsophiaxu@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

ruifangxupiao@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区永安路95号

研究负责人通讯地址:

北京市西城区永安路95号

Applicant address:

95 Yongan Road, Xicheng District, Beijing, China

Study leader's address:

95 Yongan Road, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京友谊医院

Applicant's institution:

Beijing Friendship Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京友谊医院

Affiliation of the Leader:

Beijing Friendship Hospital ,Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026-P2-303-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京友谊医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of Beijing Friendship Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-25 00:00:00

伦理委员会联系人:

李悦

Contact Name of the ethic committee:

Li Yue

伦理委员会联系地址:

北京市西城区永安路95号

Contact Address of the ethic committee:

95 Yongan Road, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 63139006

伦理委员会联系人邮箱:

Contact email of the ethic committee:

13661202501@163.com

研究实施负责(组长)单位:

首都医科大学附属北京友谊医院

Primary sponsor:

Beijing Friendship Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区永安路95号

Primary sponsor's address:

95 Yongan Road, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院

具体地址:

北京市西城区永安路95号

Institution
hospital:

Beijing Friendship Hospital ,Capital Medical University

Address:

95 Yongan Road, Xicheng District, Beijing, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-raised

研究疾病:

乳腺良性、恶性结节  

Target disease:

benign and malignant breast lesions

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

1.探究多模态超声技术对于良恶性乳腺病变的诊断价值; 2.探究多模态超声对于乳腺癌分型、预后及淋巴结转移等风险的评估价值; 3.探究多模态超声技术联合超声引导下介入诊疗对于乳腺病变诊疗效能的提升价值。  

Objectives of Study:

1. To explore the diagnostic value of multimodal ultrasonography in differentiating benign and malignant breast lesions; 2. To investigate the value of multimodal ultrasonography for evaluating molecular subtype, prognosis and risks of lymph node metastasis in breast cancer; 3. To explore the improved diagnostic and therapeutic efficacy of multimodal ultrasonography combined with ultrasound-guided interventional procedures for breast lesions.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.临床及影像学检查发现乳腺病变,拟行多模态超声检查及超声引导下介入诊疗的患者; 2.符合行超声引导下介入诊疗(旋切/消融)的适应症: (1)经粗针穿刺活检证实为良性的乳腺病变; (2)乳腺结节最大径≤3.0 cm;如果最大径≥3.0 cm或者数量过多患者可考虑分次消融。

Inclusion criteria

1.Patients with clinically or radiologically identified breast lesions undergoing multimodal ultrasonography and ultrasound-guided interventional management; 2.Eligibility criteria for ultrasound-guided interventional therapy (vacuum-assisted excision or ablation) were defined as follows, referencing literature : (1) Breast lesions confirmed benign via core needle biopsy; (2) Maximum diameter of breast nodules <= 3.0 cm. For lesions >= 3.0 cm or multiple lesions, staged ablation can be performed.

排除标准:

1.存在进行超声引导下介入诊疗禁忌症: (1) 存在严重心、肝、肾等重要脏器功能障碍,无法配合或耐受介入操作; (2)有严重出血倾向、凝血机制障碍等。 2.妊娠期及哺乳期女性; 3.无法配合检查、随访或资料不全者。

Exclusion criteria:

1.Exclusion criteria for ultrasound-guided interventional treatment: (1) Severe dysfunction of vital organs including heart, liver and kidney, resulting in intolerance or poor cooperation during interventional procedures; (2) Severe bleeding tendency or coagulation disorders. 2.Pregnant or lactating women; 3.Patients unable to cooperate with examinations or follow-up, or with incomplete clinical data.

研究实施时间:

Study execute time:

From 2026-06-14 00:00:00 To 2031-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-14 00:00:00 To 2031-05-31 00:00:00

干预措施:

Interventions:

组别:

良性组 vs.恶性组

样本量:

700

Group:

Benign group vs. Malignant group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Friendship Hospital, Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

手术成功率

指标类型:

主要指标

Outcome:

Technical success rate

Type:

Primary indicator

测量时间点:

测量方法:

超声检查

Measure time point of outcome:

Measure method:

Ultrasonographic examination

指标中文名:

评估病灶治疗范围

指标类型:

次要指标

Outcome:

Treated lesion margin assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

评估短期疗效

指标类型:

次要指标

Outcome:

Short-term therapeutic efficacy

Type:

Secondary indicator

测量时间点:

术后1个月、3个月、6个月、12个月

测量方法:

Measure time point of outcome:

1 month, 3 months, 6 months and 12 months postoperatively

Measure method:

指标中文名:

术中及术后并发症发生率

指标类型:

次要指标

Outcome:

Intraoperative and postoperative complication rates.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

准确度,特异度,敏感度

指标类型:

主要指标

Outcome:

Accuracy, Specificity, Sensitivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share the original data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

从临床研究大数据平台(医渡云系统)、超声科影像工作站及His系统查询提取、提出数据,由录入员、质控人员以及研究者分级管理数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were retrieved and extracted from three sources: the Yidu Cloud clinical big-data platform, ultrasound department image workstations, and the hospital information system (HIS). Hierarchical data management was implemented by data entry clerks, quality control personnel and investigators.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-13 18:21:15